FRAX486 – 5 mg

Brand:
Cayman
CAS:
1232030-35-1
Storage:
-20
UN-No:
Non-Hazardous - /

FRAX486 is an inhibitor of group I p21-activated kinases (PAKs; IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively).{42826} It is selective for group I PAKs over PAK4, a group II PAK (IC50 = 779 nM). FRAX486 (20 mg/kg) reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome. It completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice when administered at a dose of 30 mg/kg. FRAX486 prevents adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia.{42827}  

 

Available on backorder

SKU: 24682 - 5 mg Category:

Description

A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia,


Formal name: 6-(2,4-dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(1-piperazinyl)phenyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one

Synonyms: 

Molecular weight: 513.4

CAS: 1232030-35-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Serine/Threonine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis||Research Area|Neuroscience|Neuroprotection